Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 100 versus FLOVENT DISKUS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 100 versus FLOVENT DISKUS 250.
FLOVENT DISKUS 100 vs FLOVENT DISKUS 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and suppresses eosinophil activity.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
100 mcg inhaled orally twice daily
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
None Documented
None Documented
The terminal elimination half-life of fluticasone propionate is approximately 7.8 hours (range 5-11 hours) following inhalation. This supports twice-daily dosing, though the therapeutic effect is driven by local lung retention rather than systemic half-life.
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Fluticasone propionate is primarily eliminated via hepatic metabolism (CYP3A4) with less than 5% of a dose excreted unchanged in urine. Fecal excretion accounts for approximately 90% of the absorbed dose (as metabolites). Biliary elimination is minimal.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Category C
Category C
Corticosteroid
Corticosteroid